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Abstract
Background: CXCL12 is a pleiotropic chemokine involved in multiple different processes such as immune regulation,
inflammatory responses, and cancer development. CXCL12 is also a potent chemokine involved in chemoattraction of T cells
to the site of infection or inflammation. Mammalian target of rapamycin (mTOR) is a serine-threonine kinase that modulates
different cellular processes, such as metabolism, nutrient sensing, protein translation, and cell growth. The role of mTOR in
CXCL12-mediated resting T cell migration has yet to be elucidated.
Methodology/Principal Findings: Rapamycin, an inhibitor of mTOR, significantly inhibits CXCL12 mediated migration
of both primary human resting T cells and human T cell leukemia cell line CEM. p70
S6K1, an effector molecule of mTOR
signaling pathway, was knocked down by shRNA in CEM cells using a lentiviral gene transfer system. Using p70
S6K1 knock
down cells, we demonstrate the role of mTOR signaling in T cell migration both in vitro and in vivo.
Conclusions: Our data demonstrate a new role for mTOR in CXCL12-induced T cell migration, and enrich the current
knowledge regarding the clinical use of rapamycin.
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Introduction
Directional motility in response to a chemokine is an inherent
property of immune cells. CXCL12 or stromal cell derived factor 1-
a (SDF1-a) is a strong chemokine that governs major immune cell
migration and trafficking which is orchestrated with membrane
remodeling and cytoskeletal rearrangement including actin poly-
merization [1,2]. Several distinct signaling pathways are reported to
be involved in CXCL12-induced migration including JAK/STAT,
PI3 kinase, and MAP kinases [3,4,5,6,7]. Mammalian target of
rapamycin (mTOR) has been shown to be involved in chemokine
signaling [8,9,10]. mTOR is a serine-threonine kinase that
modulates different cellular processes, such as metabolism, nutrient
sensing, translation, and cell growth [11,12]. The contributions of
PI3 kinase and mTOR in T cell trafficking has been reported
recently [13,14]. Involvement of mTOR in chemokine mediated
migration of T and B cells has been shown recently in hypomorphic
mice generated by neo-insertion that partially affects mTOR
transcription [15]. In the presentstudy, we wanted to investigate the
involvement of mTOR, particularlythe role of p70
S6K1, an essential
downstream signaling molecule of mTOR, in CXCL12-induced T
cell migration both in vitro and in vivo. We have shown that the
migration of human peripheral blood T cells mediated by CXCL12
can be blocked by rapamycin, an inhibitor of mTOR. Using stable
T cell lines in which expression of p70
S6K1 is knocked down, we
were able to show a significant attenuation in migration in response
to CXCL12, both in vitro and in vivo. Thus our data implicate a
possible role for the mTOR pathway in CXCL12 mediated T cell
signaling and migration.
Results and Discussion
To investigate the involvement of mTOR in CXCL12-induced
T cell migration, human peripheral blood T cells were treated
with CXCL12 for 2 hour in the presence or absence of rapamycin
pretreatment, and the cell migration assay was performed using a
transwell chamber. As shown in Fig. 1A, rapamycin pretreatment
significantly inhibited CXCL12-induced T cell migration (43%
inhibition). To test whether the rapamycin-mediated blockage in
T cell migration was due to the inhibition of actin polymerization,
CXCL12-treated cells in the presence or absence of rapamycin
were stained with phalloidin, and the status of actin polymeriza-
tion was examined by confocal microscopy. As shown in Fig. 1B,
rapamycin pretreatment greatly reduced the actin polymerization
induced by CXCL12 treatment. Recently, several mTOR specific
inhibitors have been developed which are directed to the active
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1(mTORC1) and mTORC2: KU-0063794 [16], PP242 [17],
and Torin [18]. We tested the effect of one of these inhibitors (KU-
0063794) on CXCL12-induced T cell migration. As shown in
Fig. 1C, KU-0063794 had a stronger effect than rapamycin,
indicating the potency of the new generation mTOR specific
inhibitor. We also tested the effect of several other chemokines on
the migration of resting T cells and their sensitivities to rapamycin.
As shown in Fig. 1C, MIP-3b (macrophage inflammatory protein-
3beta) induced T cell migration, but this migration was insensitive
to rapamycin, which is in agreement with the recently published
data (Fig. 1C) [15]. Several other chemokines, TARC (thymus and
activation-regulated chemokine), MIP-1a & b, MCP-2 (monocyte
chemotactic protein-2) & 4, and MIG (monokine induced by
gamma interferon), were also tested for T cell migration, but were
found to be ineffective in resting T cell migration (Fig. 1C, and
data not shown).
In order to investigate the role of mTOR in CXCL12-induced
migration in more detail, we used the human T cell line CEM. As
shown in Fig. 1D, CXCL12 promoted CEM chemotaxis and
CXCL-12-induced migration of CEM cells was significantly
inhibited by rapamycin pretreatment. The maximum inhibition
(55%) was observed at 50 ng/ml concentration (Fig. 1E). Regard-
ing the clinical relevance of the rapamycin inhibitory dose, serum
concentrations of 2.7–27.1 ng/ml (2–10 mg orally/day) were
attained in a phase I trial for patients with glioblastoma [19].
Next, we developed p70
S6K1 knock down clones of CEM cells
by shRNA using a lentiviral gene transfer system. As shown in
Fig. 2A, two independent knock down clones (sh-222 and sh-224)
had about 50% reduced level of total p70
S6K1 protein as compared
to the clone carrying the empty vector (EV). CXCL12-induced
phosphorylation of p70
S6K1 was also reduced as shown in clone sh-
222 (Fig. 2B). To determine the effect of CXCL12 on 4EBP1,
another mTOR effector molecule, CEM cells were treated with
either medium alone or with CXCL12 in the presence or absence
of either rapamycin or KU-0063794 for 30 minutes, and whole
cell lysates were analyzed by western blot analysis. As shown in
Figure 2C, CXCL12 induced phosphorylation of both p70
S6K1
(Thr 389) and 4EBP1 (Thr36/47), and both of these phosphor-
ylations were blocked by rapamycin and KU-0063794. Cell
migration assay showed significantly reduced levels of CXCL12-
induced migration in sh-222 and sh-224 clones compared to the
empty vector transfected clone (EV) (Fig. 2D). The inhibition in
migration was not due to the down regulation of the cell surface
Figure 1. Rapamycin blocks CXCL12 induced migration and actin polymerization of T cells. (A) Primary human T cells were labeled with
calcein (5 mM) for 1 h in media and washed. Pretreatment of labeled cells was done with or without rapamaycin (100 ng/ml) for 1 h. Cells (1610
5 in
100 ml) were placed in the upper wells of 24-well transwell migration chambers with 5 mm pores (Corning, Corning, NY). In the lower wells, either
medium alone or CXCL12 (100 ng/ml) was added to a total volume of 600 ml, and the chambers were incubated for 2 hours at 37uC in 5% CO2
incubator. Triplicate well determinations were performed for each treatment. The level of fluorescence of cells migrating across the chamber was
assessed using a microfluorimeter. * indicates the value is statistically significant at p,0.05 level (n=4). PMI indicates ‘percent migration index’. (B)
Primary human T cells were treated with CXCL12 for 30 minutes in the presence or absence of pretreated rapamycin. Confocal microscopy was done
according to the procedure mentioned in Materials and Methods to monitor actin polymerization. Red color indicates the actin polymerization.
Representative images are shown from each treatment group. (C) Effect of rapamycin and KU-0063794 (KU) on CXCL12-induced cell migration, and
effect of MIP3b and TARC in the presence or absence of rapamycin on the migration of resting T cells were performed as described in panel A.
(D) Migration assay for CEM cells was performed similarly as primary T cells described above. (E) Dose response curve for rapamycin effect.
doi:10.1371/journal.pone.0024667.g001
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Fig. 2E. Like peripheral blood T cells, CXCL12-induced actin
polymerization was drastically reduced in sh-222 and sh-224
clones as compared to EV clone (Fig. 2F). To evaluate whether
mTOR is involved in CXCL12-induced T cell migration in vivo,
we used SCID mice to monitor the migration of clone sh-222
injected in the tail vein in response to CXCL12 applied in the
flank region. Immunohistochemistry analysis of the skin tissue
surrounding the site of injection using anti-CD4 antibody revealed
significant migration of EV clone in response to CXCL12, which
was drastically reduced in the case of clone sh-222 (Fig. 2G),
indicating the involvement of mTOR signaling in migration of T
cells in vivo against CXCL12.
It has been shown that CCL5-mediated T cell migration also
involves mTOR through induction of protein translation of cyclin
D1 and MMP-9 [9]. Since CCR5, receptor for CCL5, is only
expressed in differentiated T cells (Th1 and Th2), CCL5 does not
cause T cell chemotaxis in resting T cells [20]. On the contrary,
CXCL12 and MIP-3b induced resting T cell migration, and only
CXCL12, but not MIP3b, utilizes the mTOR pathway in T cell
chemotaxis. The involvement of mTOR in CXCL12-mediated T
cell migration is demonstrated not only by different mTOR
specific inhibitors, but also by using p70
S6K1 knock down cells, we
were able to show a significant attenuation in T cell migration in
response to CXCL12, both in vitro and in vivo. CXCL12 has been
shown to activate AKT through PI3 kinase [5,21]. AKT also
controls mTORC1 by phosphorylating and inactivating tuberous
sclerosis 2 (TSC2), the Rheb-GTPase-activating protein. Accu-
mulation of Rheb-GTP upon AKT activation results in the
activation of mTORC1 [22,23]. Besides cell migration, CXCL12
is also involved in multiple different processes such as immune
regulation, inflammatory responses, and cancer development [24].
These processes require plenty of energy. On the other hand,
mTOR is a nutrient sensor and a master regulator of translational
Figure 2. Role of mTOR in CXCL12-induced signaling and cell migration. (A) Whole cell lysates from CEM stable clones carrying either empty
vector (EV) or shRNA constructs (sh-222 and sh-224) were analyzed by western blot analysis to determine the levels of total p70
S6K1. (B) Whole cell
lysates from EV and sh-222 clones treated with CXCL12 for 30 minutes were analyzed by western blot analysis to determine the levels of phospho-
p70
S6K1. (C) CEM cells were pretreated with rapamycin (100 ng/ml) and KU-0063794 (1 mM) for 1 hour, and then CXCL12 treatment was done for 30
minutes. Equal amounts of whole cell lysates were analyzed by western blot analysis. (D) Migration assay for EV, sh-222 and sh-224 clones were
performed similarly as primary T cells described in Fig. 1A. (E) Surface expression of CXCR4 for EV, sh-222, and sh-224 were determined by FACS
analysis, and the levels are expressed as mean fluorescence intensity (MFI). (F) Confocal microscopy to monitor CXCL12-induced actin polymerization
in EV, sh-222, and sh-224 clones were performed similarly as primary T cells described in Fig. 1B. (G) In vivo migration of EV and sh-222 clone
mediated by CXCL12 was determined as described in Materials and Methods. Tissue staining from individual mice is shown here.
doi:10.1371/journal.pone.0024667.g002
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mTOR pathway to promote anabolic processes. Collectively, our
observations give insight into the future perspective regarding the
possibility of the clinical usage of rapamycin as a blocker of
CXCL12 induced T cell migration and inflammatory diseases.
Materials and Methods
Cell Culture
Peripheral blood mononuclear cells (PBMC) were collected
from healthy donors who provided informed written consent. The
protocol (ID: 2003-054) for collecting blood from normal donors
was approved by the Institutional Review Board in the National
Institute on Aging at the National Institutes of Health. PBMCs
were isolated by Ficoll-Paque density gradient centrifugation.
Total resting T cells were purified from PBMC using MACS Pan
T cell isolation kit II (Miltenyi Biotec). CEM, a human T-cell
leukemia cell line[26], and purified T cells were cultured in RPMI
1640 with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomy-
cin, and 2 mM glutamine. Cells were treated with CXCL12
(100 ng/ml) for 30 minutes in the presence or absence of
rapamycin (100 ng/ml) pretreated for 1 hour.
Reagents
Recombinant CXCL12 was purchased from Peprotech (Rocky
Hills, NJ). Rapamycin was purchased from Calbiochem (San
Diego, CA). Fluorescence calcein was purchased from Invitrogen
(Carlsbad, CA). Anti-p70
S6K1, anti-4EBP1, and anti-phospho-
4EBP1 were purchased from Cell Signaling Technology (Beverly,
MA). Anti-phospho-p70
S6K1 (Thr 389) was purchased from R&D
Systems (Minneapolis, MN). shRNA constructs against p70
S6K1
(RHS4531-NM-003161) and pGIPZ empty vector were purchased
from Open Biosystems (Huntsville, AL). Transwell chemotaxis
chambers were purchased from Corning Life Sciences (Pittsburgh,
PA).
Chemotaxis Assay
T cell migration was performed in transwell chemotaxis
chambers according to the protocol described earlier [27]. Cell
migration is expressed in percent migration index (PMI).
shRNA Stable Transfectants
shRNA plasmid (V2LHS_153622) targeting p70
S6K1, and the
appropriate empty vector, pGIPZ, were transfected into the CEM
cell line according to the method described earlier [28]. Stable
transfectants were selected by the addition of 2.0 mg/ml of
puromycin followed by single cell cloning.
Confocal Microscopy
Cells were fixed in ice cold 90% methanol in PBS for 20
minutes followed by staining for polymerized actin using
phalloidin-labeled Alexa Fluor- 594 (Invitrogen, Carlsbad, CA).
Cells were blocked with 5% BSA solution in PBS and then stained
with conjugated phalloidin overnight at 4uC. Unbound fluor-
ophores were washed with ice cold PBS mixed with 0.1% Tween-
20. Cells were subsequently cytospun on a coated slide (Fisher,
Pittsburgh, PA) and then mounted with mounting media (Prolong
Gold, Invitrogen, Carlsbad, CA). Acquisition of images was
performed using a Carl Zeiss Axiovert S100 microscope (Carl
Zeiss, Thornwood, NY). Images were deconvoluted with software
Zeiss lsm 510.
In Vivo Migration Assay
For animal study, the protocol (Protocol Number: 272-LI-2010)
was approved by the Animal Care and Use Committee in the
National Institute on Aging at the National Institutes of Health.
Equal numbers of CEM cells from either a p70
S6K1 knock down
clone or a vector containing clone were injected into the tail vein
of severe combined immunodeficiency mice (SCID). Simulta-
neously, PBS or CXCL12 (1 mgi n5 0ml) was injected subcuta-
neously to the right anterior flanking region. After 18 h, mice were
sacrificed followed by isolation of skin tissue around the point of
injection. Tissues were fixed in 4% ice-cold paraformaldehyde
overnight and were embedded in paraffin. Paraffin sections were
then deparaffinized and blocked as previously described [29],
followed by an overnight incubation at 4uCi n1 0mg/ml anti-
human CD4 antibody. Tissues were then probed with biotinylated
secondary Ab (VECTOR Laboratory) and Streptavidin-HRP
(Thermo Scientific), and developed using DAB plus substrate
system (Thermos Scientific). All slides were also counter-stained
with hematoxylin.
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